Target Discovery Platform

About Applied Cognition

Applied Cognition is pioneering a novel therapeutic approach focused on enhancing the brain's glymphatic waste clearance system to treat neurodegenerative diseases. Its core asset is a proprietary, non-invasive measurement platform that has identified targets and led to a lead small molecule combination candidate, ACX-02, which has shown early biomarker evidence of clearing amyloid and tau. The company is leveraging its platform for ongoing target discovery and drug development, positioning itself at the intersection of neuroscience, physiology, and potential AI-driven insights.

About UbiVac

UbiVac is a private, clinical-stage biotech focused on disrupting cancer treatment with its 'Dark Matter' immunotherapy platform, which targets non-mutated, shared neoantigens derived from the 'Dark Genome.' The company's lead program, DPV-001, has demonstrated compelling clinical results, including a median overall survival of 25.5 months in PD-1-naïve patients, doubling the standard-of-care benchmark. With in-house GMP manufacturing and a discovery engine aimed at identifying novel targets for multiple therapeutic modalities, UbiVac is positioned to advance a potential universal cancer vaccine while mining its platform for new drug discovery opportunities. The company is led by renowned immunotherapy expert Dr. Bernard A. Fox and is closely aligned with the Earle A. Chiles Research Institute.

Therapeutic Areas